Findings

What do systematic reviews say?

4,695 questions · 4,979 findings · 433 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 998 · 20%GRADE not reported 1,140 · 22.9%Very low 1,024 · 20.6%Low 1,029 · 20.7%Moderate 636 · 12.8%High 152 · 3.1%

Partially absorbed antifungal drug (e.g., clotrimazole, miconazole) vs Absorbed antifungal drug (e.g., fluconazole, ketoconazole, itraconazole)

Outcome not reported · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating oral candidiasis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
There were no trials comparing partially absorbed drugs with either absorbed drugs or drugs not absorbed.
0 studies
No studies found

Radiotherapy (morning) vs Afternoon radiotherapy

Locoregional control · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…

Morning radiotherapy showed no clear difference in locoregional control compared with afternoon radiotherapy; GRADE not reported.

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy 2010 · Cochrane All outcomes
HR 0.92 [0.60, 1.42]
1 study · 216 participants
GRADE not reported

Therapist support (visits) vs control (e.g. usual activities)

Daily mean opiate intake per hour · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Therapist support (visits) showed no clear difference in daily mean opiate intake per hour compared with control (treatment as usual); GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
MD 0.20 [-4.18, 4.58]
1 study · 22 participants
GRADE not reported

Morphine via patient-controlled analgesia (PCA) vs Morphine via continuous infusion (CI)

Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Morphine via patient-controlled analgesia (PCA) showed no clear difference in average pain scores (0-100 VAS) compared with morphine via continuous infusion (CI); GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
MD -2.49 [-12.28, 7.29]
3 studies · 113 participants
GRADE not reported

Debridement vs no debridement

Time to symptom resolution · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
Debridement vs no debridement (Cubukcu 2007): statistically significant benefit for debridement for days to clinical resolution; no numeric estimate reported
1 study
GRADE not reported

Vitamin E vs Placebo (not a true placebo)

Mucositis eradicated · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Vitamin E showed no clear difference in mucositis eradicated compared with placebo (not a true placebo); GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 6.00 [0.89, 40.31]
1 study · 18 participants
GRADE not reported

Morphine via pharmacokinetically based PCA (PKPCA) vs Morphine via patient-controlled analgesia (PCA)

Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Morphine via pharmacokinetically based PCA (PKPCA) led to lower average pain scores (0-100 VAS) compared with morphine via patient-controlled analgesia (PCA); GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
MD -18.00 [-31.62, -4.38]
1 study · 35 participants
GRADE not reported

Benzydamine hydrochloride mouthwash vs placebo

Improvement in mucositis · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Benzydamine hydrochloride mouthwash showed no clear difference in improvement in mucositis compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 1.22 [0.94, 1.60]
2 studies · 102 participants
GRADE not reported

Allopurinol mouthwash vs placebo

Improvement in mucositis · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Allopurinol mouthwash led to higher improvement in mucositis compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 6.33 [2.18, 18.37]
1 study · 44 participants
GRADE not reported

Allopurinol mouthwash vs placebo

Mucositis eradicated · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Allopurinol mouthwash led to higher mucositis eradicated compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 19.00 [1.17, 307.63]
1 study · 44 participants
GRADE not reported

Morphine via patient-controlled analgesia (PCA) vs Morphine via continuous infusion (CI)

Duration of pain control therapy (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Morphine via patient-controlled analgesia (PCA) led to lower duration of pain control therapy (days) compared with morphine via continuous infusion (CI); GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
MD -1.87 [-3.49, -0.25]
3 studies · 113 participants
GRADE not reported

Lower total dose radiotherapy (67.2 Gy over 5.6 weeks) vs conventional dose RT

Total mortality · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…

Lower total dose radiotherapy (67.2 Gy over 5.6 weeks) showed no clear difference in total mortality compared with conventional/standard total dose radiotherapy (72 Gy); GRADE not reported.

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy 2010 · Cochrane All outcomes
HR 1.38 [0.83, 2.29]
1 study
GRADE not reported

Sucralfate vs Salt and soda mouthwash

Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Sucralfate showed no clear difference in time to heal mucositis (days) compared with salt and soda mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
MD 13.10 [-6.30, 32.50]
1 study · 28 participants
GRADE not reported

Sucralfate vs Salt and soda mouthwash

Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Sucralfate showed no clear difference in average pain scores (0-100 VAS) compared with salt and soda mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
MD -0.30 [-1.03, 0.43]
1 study · 29 participants
GRADE not reported

Allopurinol mouthwash vs placebo

Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Allopurinol mouthwash led to lower time to heal mucositis (days) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
MD -4.50 [-5.77, -3.23]
1 study · 44 participants
GRADE not reported

Hydromorphone vs morphine

Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Hydromorphone showed no clear difference in average pain scores (0-100 VAS) compared with morphine; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
MD 0.60 [-9.24, 10.44]
1 study · 56 participants
GRADE not reported

Vitamin E (topical) vs vitamin E

Mucositis eradicated · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Vitamin E (topical) led to higher mucositis eradicated compared with vitamin E (swallowed); GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 53.74 [3.41, 846.84]
1 study · 63 participants
GRADE not reported

Pre-operative radiotherapy (plus surgery) vs surgery

Total mortality · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…

Pre-operative radiotherapy (plus surgery) showed no clear difference in total mortality compared with surgery alone; GRADE not reported.

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy 2010 · Cochrane All outcomes
HR 0.83 [0.64, 1.07]
1 study
GRADE not reported

Morphine vs Tricyclic antidepressant (nortriptyline)

Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Morphine led to lower average pain scores (0-100 VAS) compared with tricyclic antidepressant (nortriptyline); GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
MD -19.10 [-31.01, -7.19]
1 study · 39 participants
GRADE not reported

Accelerated radiotherapy (no split, boost or hyperfractionation) vs Conventional (standard) fractionation radiotherapy

Locoregional control · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy 2010 · Cochrane All outcomes
Accelerated vs conventional, locoregional control: one trial (Skladowski 2006); a statistically significant difference in favour of the altered fractionation was shown (Analysis 1.2). No numeric estimate given.
1 study
GRADE not reported